Skip to main content
  1. Right Decisions
  2. Back
  3. Dermatology pathways
  4. Melanoma
Announcements and latest updates

Right Decision Service newsletter: October 2024

Welcome to the Right Decision Service (RDS) newsletter for October 2024.

1.Contingency arrangements for RDS outages

Development of the contingency solutions to maximise RDS resilience and minimise risk of future outages is in progress, aiming for completion by Christmas. As a reminder, these contingency arrangements  are:

  • Optimising mobile app build process
  • Mobile app always to be downloadable.
  • Serialising builds to mobile app; separate mobile app build from other editorial and end-user processes
  • Load balancing – provides failover (also enables separation of editorial processes from other processes to improve performance.)

 

In the meantime, a gentle reminder to encourage users to download essential clinical toolkits to their mobile devices so that there is an offline version always available.

 

2. New deployment with improvements.

A new scheduled deployment with minor improvements drawn from support tickets, externally funded projects, information related to outages, and feature requests will take place in early December. Key improvements planned are:

  • Deep-linking to individual toolkits within the RDS mobile app. Each toolkit will now have its own direct URL and QR code, both accessible from the app. These can be used to download the toolkit directly where users already have the RDS app installed. If the user does not yet have the RDS app installed, they will be taken to the app store to install the app and immediately afterwards the toolkit will automatically open and download. Note that this will go live a few days later than the improvements below due to the need to link up the mobile front end to the changes in the content management system.
  • Introducing an Announcement Header field to replace the hardcoded "Announcements and latest updates" text. This will enable users to see at a glance the focus of new announcements.
  • Automated daily emptying of the recycling bin (with a 30 day rolling grace period)  in the content management system. A bug preventing complete emptying of the recycling bin contributed to one of the outages earlier this year.
  • Supporting multiple passcodes (ticket 6079)
  • Expanding accordion section to show location of a search result rather than requiring user coming from a search result to manually open all sections and search again for the term.
  • Displaying first accordion section Content text as a snippet on the search results page as a fallback if default/main content is not provided
  • Displaying the context of each search result in the form of a link to the relevant parent tool/section. This will help users to choose which search result is most likely to be appropriate for their needs.
  • As part of release of the new national benzodiazepine quality prescribing guidance toolkit sponsored by Scottish Government Effective Prescribing and Therapeutics, a digital tool to support creation of benzodiazepine tapering/withdrawal schedules.

We are also seeking approval to use the NHS Scotland logo and title for the RDS app on the app stores to help with audience engagement and clarity around the provenance of RDS.

3. RDS Search, Browse and Archive/Version control enhancements

We are still hopeful that user acceptance testing for at least the Search and browse enhancements can take place before Christmas. Thank you for your patience and understanding in waiting for these improvements. Timescales have been pushed back by old app migration challenges, work to address outages, and most recently implementing the contingency arrangements.

4. Support tickets

We are aware that there continue to be some issues around a number of RDS support tickets, in part due to constraints around visibility for the RDS team of the tickets in the existing  support portal. We are investigating the potential to move to a new support ticket requesting system from early in the new year. We will organise the proposed webinar around support ticket processes once we have confirmed the way forward with the system.

Table formatting

There is a known issue with alterations in formatting of some RDS tables which seems to have arisen as a result of the 17 October deployment. Tactuum is working on a fix and on implementing additional regression testing to prevent this issue recurring.

5. New RDS toolkits

Recently launched toolkits include:

NHS Lothian Infectious Diseases

Scottish Health Technologies Group – Technology Assessment recommendations

NHS Tayside Anaesthetics and Critical Care projects – an innovative toolkit which uses PowerAutomate to manage review and response to proposals for improvement projects.

If you would like to promote one of your new toolkits through this newsletter, please contact ann.wales3@nhs.scot

A number of toolkits are expected to go live before Christmas, including:

  • Focus on dementia
  • Highland Council Getting it Right for Every Child
  • Dumfries and Galloway Adult Support and Protection procedures
  • National Waiting Well toolkit
  • Fertility Scotland National Network
  • NHS Lothian postural care for care homes

6.Sign up to RDS Editors Teams channel

We have had a good response to the recent invitation to sign up to the new Teams channel for RDS editors. This provides a forum for editors to share learning, ideas and questions and we hope to hold regular webinars on topics of interest.  The RDS team is in the process of joining participants to the channel and we’d encourage all editors to take part, using the registration form – available in Providers section of the RDS Learning and Support area.

 

7. Evaluation projects

The RDS team has worked with colleagues in NHS Grampian and the Digital Health & Care Innovation Centre to evaluate the impact of the Prevent the progress of diabetes web and mobile app in a small-scale pilot project. This app provides access to local and national resources and services targeted at people with prediabetes, a history of gestational diabetes, or candidates for remission. After just 8 weeks of using the app, 94% of patients reported increased their knowledge and understanding of diabetes, and 88% said it had increased their confidence and motivation to make lifestyle changes, highlighting specific behaviour changes. The learning from this project is informing development of a service model based on tailored support for patient groups with, high, medium and low digital self-efficacy.

Please contact ann.wales3@nhs.scot if you would like to know more about this project.

  1. Training sessions for new editors (also serve as refresher sessions for existing editors) will take place on the following dates:

  • Friday 29th November 3-4 pm
  • Thursday 5 December 3.30 -4.30 pm

To book a place, please contact Olivia.graham@nhs.scot, providing your name, organisation, job role, and level of experience with RDS editing (none, a little, moderate, extensive.)

 

To invite colleagues to sign up to receive this newsletter, please signpost them to the registration form  - also available in End-user and Provider sections of the RDS Learning and Support area.   If you have any questions about the content of this newsletter, please contact his.decisionsupport@nhs.scot  If you would prefer not to receive future newsletters, please email Olivia.graham@nhs.scot and ask to be removed from the circulation list.

With kind regards

 

Right Decision Service team

Healthcare Improvement Scotland

 

The Right Decision Service:  the national decision support platform for Scotland’s health and care

Website: https://rightdecisions.scot.nhs.uk    Mobile app download:  Apple  Android

 

 

Melanoma

Warning

Cutaneous Melanoma: A skin cancer of the melanocytes in the skin. Melanoma is the third most common skin cancer in the UK. It accounts for more cancer deaths than all other skin cancers combined. Although melanoma is more often diagnosed in older people, it is increasingly affecting younger people. It is the second most common cancer in adults aged between 25 and 49. Most melanomas occur in people with pale skin. Precursor lesions include acquired and large congenital melanocytic naevi (moles), and dysplastic naevi but at least 50% appear with no preceding lesion. Several histologic variants have been recognized, including superficial spreading melanoma, acral lentiginous melanoma, nodular melanoma, and lentigo maligna melanoma.  

 

Please see key messages with scenarios outlining common situations where people have benign lesions that cause some concern and need additional evaluation over time. 

 

Scottish Referral Guidelines for suspected cancer are available at the following link - https://www.cancerreferral.scot.nhs.uk/Home 

Not all treatment options may be listed in this guidance. Please refer to local formulary for a complete list.

Treatment/ therapy

Benign: 

Referral is not usually required for obviously benign lesions, Features which are generally reassuring and suggest a benign lesion include: 

  • Regularity of colour, surface, and border. 
  • Rapid growth over days rather than weeks – common with trauma or inflammation. 
  • 'Stuck on' appearance with keratotic plugs on the surface (suggests a seborrhoeic keratosis). 
  • A pigmented lesion in a child (melanoma is very rare in this age group). 

Risk evaluation: 

Risk evaluation indicating at risk people includes the following: 

  • A personal history of skin cancer.  
  • A family history of skin cancer.  
  • Pale skin (Fitzpatrick Skin Type I and II) that burns easily.  
  • Red, blonde or light-coloured hair. 
  • Blue or green eyes. 
  • History of sunburn, particularly blistering sunburn in childhood. 
  • A large number of moles. 
  • Unusually high sun exposure (living or spending frequent periods in hot countries). 
  • Use of tanning beds or sun beds, particularly if 10 or more sessions.  
  • Increasing age.  
  • Immunosuppression 
  • Pigmented lesions which 'stand out from the crowd' because they are different (the 'Ugly Duckling sign') are a cause for concern, especially if they are changing.  

The Weighted 7-point checklist may be used to assess pigmented skin lesions, and determine referral:  

o Major features of the lesion (2 points each): change in size, irregular shape or border, irregular colour. 

o Minor features of the lesion (1 point each): largest diameter 7 mm or more, inflammation, oozing or crusting of the lesion, change in sensation (including itch). 

o Suspicion is greater for lesions scoring 3 points or more. However, if there are strong concerns about cancer, any one feature is adequate to prompt urgent referral under Urgent Suspicion Of Cancer (USOC) arrangements.

The ABCD(E) system can also be used for pigmented lesion assessment (http://www.pcds.org.uk/clinical-guidance/melanoma-an-overview1) 

 

Refer using a Routine priority (as long as there is no index lesion of concern, where USOC needed) for risk estimation if people are at higher risk of melanoma, such as those with: 

  • Giant congenital pigmented naevi (risk is highest for those measuring 20 cm in diameter or more). 
  • A family history of 3 or more cases of melanoma and/or family history of pancreatic cancer— Those with two cases in the family may also benefit, especially if one of the cases had multiple primary melanomas or the atypical mole phenotype.  
  • More than 100 normal moles. 

Atypical moles, see: https://www.pcds.org.uk/clinical-guidance/atypical-dysplastic-melanocytic-naevus  (particularly if multiple). 

Possible malignant: 

Urgently refer (using USOC, or similar, urgent pathway) to a dermatologist, plastic surgeon, or other suitable specialist with experience of melanoma diagnosis if: 

  • The lesion is suggestive of malignant melanoma (including nodular and amelanotic melanoma). For example: 
  • Lesions scoring 3 points or more (based on major features scoring 2 points each and minor features scoring 1 point each) on the 7-point checklist. However, any one feature is adequate to prompt urgent referral. 
  • New nodules which are pigmented or vascular in appearance. 
  • Nail changes, such as a new pigmented line in the nail or pigmentation under the nail that differs from other nails. 
  • A skin condition is persistent or slowly evolving and unresponsive, with an uncertain diagnosis, and melanoma is a possibility. 
  • A biopsy has confirmed the diagnosis of malignant melanoma. Note: normally such patients would be referred prior to excision. 

A copy of the pathology report should be sent with the referral correspondence, as there may be details (such as tumour thickness, excision margin) that will specifically influence further management.

Scottish Referral Guidelines for suspected cancer are available at the following link - https://www.cancerreferral.scot.nhs.uk/Home 

Referral Management

Benign: 

Manage in primary care. Consider scenarios 1 to 3 in Key messages. Review access to alternative providers for patient access to benign lesion treatments outside the NHS. 

Risk evaluation: 

 

Possible malignant: 

Refer using the USOC pathway for skin cancer. 

 

Scottish Referral Guidelines for suspected cancer are available at the following link - https://www.cancerreferral.scot.nhs.uk/Home 

Clinical tips

  • Lesions change over time and a benign diagnosis at initial assessment may need to be reviewed if the lesion changes. Initial safety netting by check in 3 months against baseline photos is current NICE guidance for lesions with some measure of uncertainty. For itchy benign-appearing lesions causing uncertainty, see scenario 2 in Key Messages. 
  • Photography is key for monitoring of lesions, sharing the diagnostic process and helping patients self-monitor. It improves the quality of the GP record and can be used for teledermatology. See scenarios below illustrating common dilemmas 

Scenario 1  

Low suspicion of malignancy: teledermatology may be used outside the USOC process, where locally available. Include a stable non-changing clinically benign skin lesion, but where the clinical diagnosis is uncertain and doesn’t satisfy 7 point checklist. Suitable photos are essential: 

take at least 3 images of the lesion, once indicated with an inked arrow or circle, including:  

  • regional photograph with lesion indicated with ink.  
  • macro image plane and at an angle.  
  • dermoscopic image with and without gel/polarisation.  

Include core history: 

  • see Risk Evaluation: e.g. evolution, symptoms, skin type, family history, eye colour, episodes of burning, high mole count.  

Scenario 2 

For a pigmented lesion which does not satisfy criteria for referral but is difficult to evaluate, consider the following: 

  • Take a photograph (see scenario 1)  
  • Ask a senior colleague with additional expertise/dermoscopy skills.  
  • Where the lesion is itchy and suspicious for seborrhoeic keratosis take a photo, use emollient and moderate potency steroid for 3 weeks and review to ensure return to previous appearance. 

Scenario 3  

For someone with multiple pigmented lesions which appear benign but give rise to uncertainty: 

  • Highlight with ink (number and arrow) those that warrant monitoring or assessment and take regional /macro/dermoscopy photos. Suggest patient participates in self-monitoring with Apps (review NHS Apps). Failure to number them in regional photo will risk misidentification. 
  • If atypical see “risk evaluation” 

ICD search categories

Malignant 

ICD11 code - 2C30 

Editorial Information

Last reviewed: 24/05/2023

Next review date: 24/05/2025

Author(s): Adapted from the BAD Referral Guidelines.

Version: BAD 1

Co-Author(s): Publisher: Centre for Sustainable Delivery, Scottish Dermatological Society.

Approved By: Scottish Dermatological Society